ARCHIVES

Nixon Resignation Won’t Hurt Cancer Program, Might Lead To More Money; Weinberger Stays

This article is from The Cancer Letter archive.

Vol. 01 No. 28 | August 16, 1974

Download PDF Visit The Full Archive

Related Articles

Feinstein Reintroduces New National Cancer Act

June 13, 2003

Core Grants Limit Formula Must Wait On Profiles

January 27, 1978

Two Regorafenib Trials Demonstrate Efficacy, Improve Overall and Progression-Free Survival

December 28, 2012

J&J To Eliminate Its Ortho Biotech Unit As FDA Considers Further Limits On ESAs.

May 2, 2008

NCI Director Halts STELLAR Trial, Seeks “Brilliant Ideas” For Breast Cancer Prevention.

March 2, 2007

Clinical Trials: Institutions Invited By NSABP To Join Raloxifene Trial

July 10, 1998